vs
Side-by-side financial comparison of Ranpak Holdings Corp. (PACK) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $93.7M, roughly 1.4× Ranpak Holdings Corp.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 2.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 13.7%).
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PACK vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.7M | $129.7M |
| Net Profit | — | — |
| Gross Margin | 39.0% | 98.0% |
| Operating Margin | -1.0% | -25.0% |
| Net Margin | — | — |
| Revenue YoY | 2.3% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.11 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.7M | $129.7M | ||
| Q3 25 | $83.6M | $164.9M | ||
| Q2 25 | $77.8M | $114.4M | ||
| Q1 25 | $77.6M | $81.7M | ||
| Q4 24 | $91.6M | $74.8M | ||
| Q3 24 | $78.6M | $62.9M | ||
| Q2 24 | $72.8M | $54.1M | ||
| Q1 24 | $72.5M | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-10.4M | $25.7M | ||
| Q2 25 | $-7.5M | $-12.8M | ||
| Q1 25 | $-10.9M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.1M | $-54.8M | ||
| Q2 24 | $5.5M | $-70.4M | ||
| Q1 24 | $-8.1M | $-136.1M |
| Q4 25 | 39.0% | 98.0% | ||
| Q3 25 | 41.1% | 99.0% | ||
| Q2 25 | 37.1% | 98.7% | ||
| Q1 25 | 39.8% | 94.3% | ||
| Q4 24 | 45.2% | 96.6% | ||
| Q3 24 | 43.8% | 97.4% | ||
| Q2 24 | 43.5% | 96.2% | ||
| Q1 24 | 44.6% | 96.4% |
| Q4 25 | -1.0% | -25.0% | ||
| Q3 25 | -6.8% | 15.1% | ||
| Q2 25 | -12.5% | -11.1% | ||
| Q1 25 | -10.3% | -52.2% | ||
| Q4 24 | 1.5% | -81.2% | ||
| Q3 24 | -5.3% | -89.3% | ||
| Q2 24 | -7.1% | -125.1% | ||
| Q1 24 | -6.6% | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | -12.4% | 15.6% | ||
| Q2 25 | -9.6% | -11.1% | ||
| Q1 25 | -14.0% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.3% | -87.1% | ||
| Q2 24 | 7.6% | -130.1% | ||
| Q1 24 | -11.2% | -328.9% |
| Q4 25 | $-0.11 | $0.04 | ||
| Q3 25 | $-0.12 | $0.28 | ||
| Q2 25 | $-0.09 | $-0.14 | ||
| Q1 25 | $-0.13 | $-0.47 | ||
| Q4 24 | $-0.13 | $-0.71 | ||
| Q3 24 | $-0.10 | $-0.70 | ||
| Q2 24 | $0.07 | $-0.91 | ||
| Q1 24 | $-0.10 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $93.0M |
| Total DebtLower is stronger | $401.9M | — |
| Stockholders' EquityBook value | $534.9M | $114.8M |
| Total Assets | $1.1B | $605.2M |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $93.0M | ||
| Q3 25 | $49.9M | $110.9M | ||
| Q2 25 | $49.2M | $75.2M | ||
| Q1 25 | $65.5M | $61.9M | ||
| Q4 24 | $76.1M | $58.5M | ||
| Q3 24 | $69.5M | $36.4M | ||
| Q2 24 | $65.1M | $32.3M | ||
| Q1 24 | $55.1M | $43.3M |
| Q4 25 | $401.9M | — | ||
| Q3 25 | $403.1M | — | ||
| Q2 25 | $403.1M | — | ||
| Q1 25 | $405.2M | — | ||
| Q4 24 | $406.4M | — | ||
| Q3 24 | $403.2M | — | ||
| Q2 24 | $396.1M | — | ||
| Q1 24 | $396.7M | — |
| Q4 25 | $534.9M | $114.8M | ||
| Q3 25 | $537.8M | $73.6M | ||
| Q2 25 | $539.0M | $32.7M | ||
| Q1 25 | $544.1M | $32.8M | ||
| Q4 24 | $548.1M | $59.1M | ||
| Q3 24 | $564.3M | $-30.5M | ||
| Q2 24 | $566.2M | $15.1M | ||
| Q1 24 | $560.0M | $74.1M |
| Q4 25 | $1.1B | $605.2M | ||
| Q3 25 | $1.1B | $538.6M | ||
| Q2 25 | $1.1B | $555.3M | ||
| Q1 25 | $1.1B | $548.8M | ||
| Q4 24 | $1.1B | $594.1M | ||
| Q3 24 | $1.1B | $504.4M | ||
| Q2 24 | $1.1B | $551.1M | ||
| Q1 24 | $1.1B | $663.5M |
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.71× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.5M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.5M | $60.7M | ||
| Q3 25 | $8.5M | $14.3M | ||
| Q2 25 | $-3.6M | $5.0M | ||
| Q1 25 | $-1.3M | $-42.2M | ||
| Q4 24 | $6.5M | $-35.7M | ||
| Q3 24 | $10.1M | $-42.5M | ||
| Q2 24 | $19.6M | $-40.2M | ||
| Q1 24 | $5.2M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.56× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
